癌症中PRC2失活突变通过增强病毒拟态提升对DNMT1靶向治疗的细胞毒反应
该研究在高恶性外周神经鞘瘤(MPNST)中通过RNAi筛选发现,PRC2失活增加对DNMT1遗传或小分子抑制的敏感性,导致细胞毒性和抗肿瘤反应增强。机制上,PRC2失活放大DNMT抑制剂介导的逆转录转座子表达、病毒拟态反应及部分依赖PKR的双链RNA传感器介导的细胞死亡。
要点
- PRC2失活突变使MPNST对DNMT1抑制敏感。
- PRC2失活增强DNMT抑制剂诱导的逆转录转座子表达和病毒拟态。
- 细胞死亡部分依赖PKR依赖的双链RNA传感器。
核心结论
- PRC2失活突变通过增强病毒拟态和细胞毒性,为DNMT1靶向治疗提供肿瘤背景特异性干预机会。
研究设计与样本
- 在MPNST中进行RNAi筛选,并验证PRC2失活对DNMT1抑制的敏感性。
主要发现
- PRC2失活增加对DNMT1遗传或小分子抑制的敏感性,增强细胞毒性和抗肿瘤反应。
- PRC2失活放大DNMT抑制剂介导的逆转录转座子表达和病毒拟态反应。
- 细胞死亡部分通过PKR依赖的双链RNA传感器实现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Polycomb repressive complex 2 (PRC2) has oncogenic and tumor-suppressive roles in cancer. There is clinical success of targeting this complex in PRC2-dependent cancers, but an unmet therapeutic need exists in PRC2-loss cancer. PRC2-inactivating mutations are a hallmark feature of high-grade malignant peripheral nerve sheath tumor (MPNST), an aggressive sarcoma with poor prognosis and no effective targeted therapy. Through RNAi screening in MPNST, we found that PRC2 inactivation increases sensitivity to genetic or small-molecule inhibition of DNA methyltransferase 1 (DNMT1), which results in enhanced cytotoxicity and antitumor response. Mechanistically, PRC2 inactivation amplifies DNMT inhibitor-mediated expression of retrotransposons, subsequent viral mimicry response, and robust cell death in part through a protein kinase R (PKR)-dependent double-stranded RNA sensor. Collectively, our observations posit DNA methylation as a safeguard against antitumorigenic cell-fate decisions in PRC2-loss cancer to promote cancer pathogenesis, which can be therapeutically exploited by DNMT1-targeted therapy. SIGNIFICANCE: PRC2 inactivation drives oncogenesis in various cancers, but therapeutically targeting PRC2 loss has remained challenging. Here we show that PRC2-inactivating mutations set up a tumor context-specific liability for therapeutic intervention via DNMT1 inhibitors, which leads to innate immune signaling mediated by sensing of derepressed retrotransposons and accompanied by enhanced cytotoxicity. See related commentary by Guil and Esteller, p. 2020. This article is highlighted in the In This Issue feature, p. 2007.
引用
- Patel AJ, Warda S, Maag JLV, et al. PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer Discov. 2022. PMID: 35789380. doi:10.1158/2159-8290.CD-21-1671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。